Skip to main content
. 2018 Mar 13;8:4448. doi: 10.1038/s41598-018-22791-y

Figure 4.

Figure 4

Prolyl hydroxylase inhibitor (PHDi) ameliorates anemia of prematurity. Administration of PHDi increased EPO mRNA (a), serum EPO levels (b), RBC counts, hematocrit levels, and hemoglobin levels (c) at P7 (n = 4). Error bars indicate SEM. *P < 0.05 by t-test. In the graph of mRNA expression, arbitrary unit is used for vertical axis. PHDi, prolyl hydroxylase inhibitor; Ctrl, control; RBC, red blood cells.